
Small Molecules of the Month March 2021





HO

LSN3318839 01


- 02 GLPG1972 / S201086
- 03 BMS-986224
- 04 encequidar
- 05 S62798
- 06 CVN424
- **O7 ABBV-167**
- 80 GDC-0310
- "compound 72" 09
- 10 "compound 20"
- 77 **TAK-418**
- **GSK716 (13)** 12
- **RBN-012759** 13
- 14 sisunatovir

Lilly Research Laboratories Galapagos SASU Bristol Myers Squibb Athenex / Hanmi Pharmaceutical Servier **Cerevance / Takeda California** AbbVie Genentech Merck & Co Genentech **Takeda Pharmaceuticals** GlaxoSmithKline **Ribon Therapeutics Reviral Ltd.**



LSN3318839

Lilly Research Laboratories




The Lilly glucagon-like peptide-1 receptor (GLP-1R) agonist (LSN3318839) is a positive allosteric modulator intended to treat type 2 diabetes. This drug candidate has an interesting proposed mechanism as a molecular glue between GLP-1R and GLP peptide, enhancing endogenous peptide activity.

The starting point was identified from a 220k compound cell-based screen in the presence of GLP-1 peptide, and optimization of PK of prior lead LSN3160440 led to LSN3318839. Oral administration of LSN3318839 (30 mg/kg) results in a blood glucose lowering effect in animal models, which is additive with sitaglipin administration. It is the first characterized molecular glue for GPCRs with demonstrated in vivo efficacy.

GLP-1R/GLP molecular glue agonist (PAM)
Oral blood glucose↓, additive w/ sitaglipin
From 220k cmpd cell-based screen + PK opt.
J. Med. Chem., Mar. 15, 2021
Lilly Research Laboratories, Indianapolis, IN

GLPG1972 / S201086

Galapagos SASU




The Galapagos–Servier selective ADAMTS–5 metalloproteinase inhibitor (<u>GLPG1972</u>) recently completed a Ph. II study for knee osteoarthritis. Identification of small molecule clinical candidates for metalloproteinases is challenging due to selectivity issues and the chemical properties of needed metal–binding groups.

The hydantoin is proposed to act as a bidentate zinc-binding motif (see <u>this paper</u> for an X-ray co-crystal structure of a hydantoin inhibitor coordinated to zinc). The mechanism of action targeting cartilage is interesting but the compound <u>did not meet its primary or</u> <u>secondary endpoints</u> in its recent Ph. II trial.

Zinc-binding ADAMTS-5 metalloproteinase inh.
Oral candidate in Ph. II for osteoarthritis
50k cmpd HTS enriched for zinc-binding + opt.
J. Med. Chem., Mar. 15, 2021
Galapagos SASU, FR / Servier, FR

BMS-986224

Bristol Myers Squibb



Oral apelin receptor GPCR agonist Completed Ph. I for heart failure, discontinued From cell-based HTS and opt. J. Med. Chem., Mar. 19, 2021 Bristol Myers Squibb, Princeton, NJ


drug hunter

The Bristol Myers Squibb apelin receptor (APJ) GPCR agonist ("compound 14") is a clinical candidate for heart failure which completed a Ph. I study. Endogenous pyroglutamated apelin-13 peptide has been shown to be beneficial in cardiovascular disease models, and this small molecule agonist was intended to treat heart failure by mimicking apelin-13 peptide without the stability and delivery issues of a peptide approach.

This drug candidate has impressive PK in preclinical species despite its structure containing several groups that can be difficult to deal with, including a phenol, pyridine, several ethers, a pyridine, and two benzylic positions. In a rat model, compound 14 treatment results in an increase in cardiac output without significant increase in heart rate in contrast to currently used inotropes such as dobutamine. Development appears to have been discontinued.

encequidar

Athenex / Hanmi Pharmaceutical




Gut-restrict. P-gp inh. for oral paclitaxel combo Efficacious in Ph. III, NDA filed but CRL issued From opt. of tariquidar J. Med. Chem., Mar. 17, 2021 Athenex / Hanmi Pharmaceutical, Seoul, KR The Athenex/Hanmi Pharmaceutical P-gp transporter inhibitor (encequidar) is a gut-restricted compound intended to reduce efflux and increase absorption of the IV drug, paclitaxel to enable oral paclitaxel delivery. The use of transporter inhibitors in preclinical settings to improve drug exposure is well-established, and similar use in humans in various contexts has been often discussed but has seen little success.

This drug is an interesting overall case study for deliberately inducing a DDI, leveraging a transporter inhibitor to make an IV drug (paclitaxel) orally bioavailable, and the paper covers preclinical and clinical development in detail.

Oral combination of encequidar and paclitaxel demonstrated efficacy and tolerability with reduced neuropathy and no hypersensitivity (since the IV excipient polyoxyl-35 castor oil was obviated) in a Ph. III study in metastatic breast cancer. While the drug appears to work as intended and an NDA was filed, the FDA recently issued a **complete response letter** recommending additional studies.


drug hunter



04

S62798

Servier



Fibrinolytic TAFIa carboxypeptidase inhibitor Ph. II candidate for pulm. embolism; discont. From literature pharmacophore and SBDD J. Med. Chem., Mar. 25, 2021 Servier, Croissy-sur-Seine, FR

drug hunter


The Servier thrombin activatable fibrinolysis inhibitor (TAFIa) inhibitor (S62798) is a fibrinolytic (clot degrading) agent which entered Ph. II in the EU for pulmonary embolism, but development appears to have been cancelled. TAFIa inhibitors are suggested to reduce clotting risk without the risk of major hemorrhage since they don't interfere with platelet activation and blood coagulation. The phosphinic acid acts as a zinc binding motif, and was cyclized in order to reduce conformational flexibility and increase selectivity against other carboxypeptidases.

This phosphorus-containing molecule has interesting drug properties as it is a highly polar, renally excreted compound possessing two acidic sites and multiple potentially basic atoms. The binding mode is also interesting with numerous highly polar interactions including zinc metal-binding within a short distance of one another. I.V. administration of S62798 in mice accelerated clot degradation and blood vessel recanalization as intended, which could be useful for treating pulmonary embolism or ischemic stroke.



CVN424

Cerevance / Takeda California



The Cerevance/Takeda GPR6 inverse agonist (CVN424) is an oral, once-daily clinical candidate in Ph. II for Parkinson's disease after completing a Ph. I in healthy volunteers. Its >40 μ M starting point was discovered through a 360k compound cell-based HTS targeting human GPR6 (an orphan GPCR).

The molecule CVN424 is interesting because it is brain penetrant and orally available even with five rings and numerous polar atoms and metabolic soft spots. In vivo, CVN424 increases locomotor activity, reverses haloperidol induced catalepsy and restores mobility in a bilateral 6-OHDA lesion model of Parkinson's disease.

With its non-dopaminergic mechanism, CVN424 is a potential drug for treating the motor symptoms of PD with a reduced risk of adverse effects such as L-DOPA induced dyskinesias.


CNS pen. GPR6 GPCR inverse agonist Oral QD Ph. II candidate for Parkinson's From 360k cmpd cell-based HTS + opt. J. Pharmacol. Exp. Ther., Apr. 1, 2021 Cerevance / Takeda California, San Diego, US

drug



ABBV-167






The AbbVie BCL-2 inhibitor prodrug (<u>ABBV-167</u>) is a phosphate prodrug of venetoclax used for treatment of chronic lymphocytic leukemia (CLL). This molecule has an interesting prodrug mechanism, masking an azaindole heterocycle through heterocycle N-alkylation.

By improving the solubility, the dose needed of this prodrug relative to parent was greatly reduced, nicely illustrated with pill pictures in the manuscript. A clinical study on healthy volunteers revealed that both solid and liquid dosage forms of ABBV-167 significantly improve the bioavailability of venetoclax under fasted conditions and reduce the food effect with respect to venetoclax.

Venetoclax prodrug with reduced food effect Enhanced bioavailability in healthy volunteers From venetoclax heterocycle N-alkylation Mol. Cancer. Ther. Mar. 30, 2021 AbbVie, North Chicago, IL

GDC-0310


Genentech



Zwitterionic oral selective Nav1.7 inh. for pain Predicted QD dosing, completed Ph. I, discont. PK optimization of prior scaffold J. Med. Chem., Mar. 8, 2021 Genentech, South San Francisco, CA / Xenon

The Genentech Nav1.7 inhibitor (GDC-0310) is a oral Ph. I clinical candidate for pain. Nav1.7 has been a hot target for pain, and we previously highlighted a Nav1.7 inhibitor as one of 2020's **Small Molecules of the Year**. It is interesting among Nav1.7 inhibitors due to the presence of a very polar amine group where highly lipophilic elements were formerly incorporated, and is also an interesting example of an orally available zwitterion with a membrane-bound target.


This acyl-sulfonamide derivative demonstrates >300-fold selectivity over Nav1.1, Nav1.5, and Nav1.6. Preclinical studies of GDC-0310 were conducted based on measuring its ability to block a response to aconitine (a plant alkaloid that causes abnormal opening of sodium channels). Unfortunately development of this molecule has been discontinued.



drug

"compound 72"

Merck & Co



The Merck protein arginine methyltransferase 5 (PRMT5) inhibitor (<u>"compound 72</u>") is a SAM cofactor-mimetic with a novel 5,5-fused carbon-based bicyclic scaffold. PRMT5 is an actively pursued epigenetic target for cancer with a flurry of research programs being published recently and several trials being initiated.


Remarkably, compound 72 has an excellent oral PK profile in higher species with a low predicted human dose of 15 mg QD, despite having 6 hydrogen bond donors and 6 rings.

Oral PRMT5 inh. for treating cancers Projected human dose of 15 mg QD w/ 6 HBD SBDD from SAM cofactor J. Med. Chem., Mar. 23, 2021 Merck & Co, Boston, MA



"compound 20"

Genentech




The Genentech transient receptor potential ankyrin 1 (TRPA1) inhibitor ("compound 20") is an ion channel inhibitor with a binding site and mechanism of action characterized by cryo-EM. Structural information for ion-channel targets is rare as X-ray co-crystal structures of membrane-bound proteins are difficult to obtain.

The article is an interesting case study for using conformational analysis to improve drug molecules, and the authors highlight several interesting attempted linker rigidification strategies. Compound 20 is orally efficacious in a guinea pig asthma model demonstrating a substantial reduction in inflammatory response due to BALF infiltrates in the airways around 10 mg/kg BID.

Cryo-EM-characterized TRPA1 ion channel inh. Oral efficacy (10 mpk BID) in asthma model Rational design from literature starting point J. Med. Chem., Mar. 22, 2021 Genentech, South San Francisco, CA

TAK-418

Takeda Pharmaceuticals



The Takeda lysine-specific demethylase 1 (LSD1) inhibitor (TAK-418) is an oral CNS-penetrant clinical candidate for neurodevelopmental disorders such as autism spectrum disorder. We previously highlighted <u>irreversible</u> and <u>reversible</u> LSD1 inhibitors intended to treat cancer.


This tranylcypromine-derived clinical candidate is interesting because it is a relatively rare example of a mechanism-based CNS-acting drug. Oral administration of TAK-418 at only 1 mg/kg normalized mRNA expression in neurodevelopmental disorder model rodents and improved sociability. The proposed mechanism of action for neurodevelopmental disorders (restoring gene expression homeostasis by inhibiting a stabilizer of faulty epigenetic machinery) will be interesting to watch.

11

Brain-penetrant LSD1 inh. for neuro. disorders Sociability ↑ in vivo, completed Ph. I in HV Tranylcypromine class mechanism-based inh. Sci. Adv., Mar. 12, 2021 Takeda Pharmaceuticals, Fujisawa, JP

GSK716 (13)


GlaxoSmithKline



The GlaxoSmithKline (GSK) Z a1-antitrypsin stabilizer (<u>"compound 13," GSK716</u>) acts by blocking the formation of polymers within the endoplasmic reticulum of hepatocytes for treatment of a1-antitrypsin deficiency. It was identified through a DNA-encoded library screen with a nominal diversity of 2 trillion components. Compound 13 showed an excellent selectivity profile toward a1-antitrypsin.


The 1 mg/kg i.v. infusion of compound 13 demonstrated moderate bioavailability in rat and was predicted to have high oral bioavailability in human. This molecule is interesting as the starting point came from a DEL screen and has a rare corrector mechanism of action.

Mutant a1-antitrypsin folding corrector Sub-µM in cell, high predicted human %F From 2T component DEL + SBDD Bioorg. Med. Chem. Lett., Mar. 19, 2021 GlaxoSmithKline, Stevenage, UK / UCL



RBN-012759

Ribon Therapeutics




>300-fold family-selective PARP14 inh. tool 90x IC50 coverage at 500 mpk BID PO in vivo From PARP-preferring directed library + SBDD Cell Chem. Bio., Mar. 10, 2021 Ribon Therapeutics, Cambridge, MA

drug hunter


The Ribon Therapeutics PARP14 inhibitor (RBN-012759) is a tool compound with >300x selectivity over all PARP family members. While PARP1/2 are well-known to drug hunters as synthetic lethal targets due to their role in DNA damage repair, there are 17 PARP enzymes with many other biological roles without as much pharmacological exploration.

The starting point for RBN-012759 was identified by screening a PARP-preferring directed library and structure-based design led to RBN-012759. Preclinical studies in mice demonstrated modest oral bioavailability of RBN-012759, but it was well tolerated over several days at 500 mg/kg BID orally, a dose that provides 90-fold coverage of the mouse PARP14-free IC50 value (15 ng/mL) at 8 h. This tool should help elucidate the role of PARP14 in anti-tumor immunity.



sisunatovir





Oral lung penetrant RSV fusion inhibitor Ph. II candidate (50 mg BID) for RSV infect. Opt. from literature starting point J. Med. Chem., Mar. 17, 2021 Reviral Ltd, Hertfordshire, UK

drug hunter


The Reviral respiratory syncytial virus (RSV) fusion inhibitor (sisunatovir) is an oral Ph. II clinical candidate that demonstrated reduction in viral load and total symptom score in RSV-infected patients and has received the Fast Track designation from the FDA. Crowded areas for development such as for RSV often lead to interesting chemical structures.

This molecule is interesting because of some less common structural motifs including a potentially reactive spirocyclic cyclopropyl oxindole and a primary amine. Despite the potential for hERG inhibition, no QT effects were observed in the guinea pig model or dog telemetry studies, and the molecule was taken through human proof of concept.

The paper describes the discovery and development thought process in detail and is a great drug discovery process case study from a smaller organization.


Small Molecules of the Month

LSN3318839



GLP-1R/GLP molecular glue agonist (PAM) Oral blood glucose↓, additive w/ sitaglipin From 220k cmpd cell-based screen + PK opt. J. Med. Chem., Mar. 15, 2021 Lilly Research Laboratories, Indianapolis, IN

BMS-986224



Oral apelin receptor GPCR agonist Completed Ph. I for heart failure, discontinued From cell-based HTS and opt. J. Med. Chem., Mar. 19, 2021 Bristol Myers Squibb, Princeton, NJ

S62798



Fibrinolytic TAFIa carboxypeptidase inhibitor Ph. II candidate for pulm. embolism; discont. From literature pharmacophore and SBDD J. Med. Chem., Mar. 25, 2021 Servier, Croissy-sur-Seine, FR

ABBV-167

Venetoclax prodrug with reduced food effect Enhanced bioavailability in healthy volunteers From venetoclax heterocycle N-alkylation Mol. Cancer. Ther. Mar. 30, 2021 AbbVie, North Chicago, IL

"compound 72"


Oral PRMT5 inh. for treating cancers Projected human dose of 15 mg QD w/ 6 HBD SBDD from SAM cofactor J. Med. Chem., Mar. 23, 2021 Merck & Co, Boston, MA


TAK-418



Brain-penetrant LSD1 inh. for neuro. disorders Sociability ↑ in vivo, completed Ph. I in HV Tranylcypromine class mechanism-based inh. Sci. Adv., Mar. 12, 2021

>300-fold family-selective PARP14 inh. tool 90x IC_{50} coverage at 500 mpk BID PO in vivo From PARP-preferring directed library + SBDD Cell Chem. Bio., Mar. 10, 2021 Ribon Therapeutics, Cambridge, MA









Takeda Pharmaceuticals, Fujisawa, JP

RBN-012759






drug hunter



March 2021 drughunter.com





H3CO CH3C



Zinc-binding ADAMTS-5 metalloproteinase inh. Oral candidate in Ph. II for osteoarthritis 50k cmpd HTS enriched for zinc-binding + opt. J. Med. Chem., Mar. 15, 2021 Galapagos SASU, FR / Servier, FR

encequidar

Gut-restrict. P-gp inh. for oral paclitaxel combo Efficacious in Ph. III, NDA filed but CRL issued From opt. of tariquidar J. Med. Chem., Mar. 17, 2021

Athenex / Hanmi Pharmaceutical, Seoul, KR

CVN424

CNS pen. GPR6 GPCR inverse agonist Oral QD Ph. II candidate for Parkinson's From 360k cmpd cell-based HTS + opt. J. Pharmacol. Exp. Ther., Apr. 1, 2021 Cerevance / Takeda California, San Diego, US

GDC-0310

Zwitterionic oral selective Na_v1.7 inh. for pain Predicted QD dosing, completed Ph. I, discont. PK optimization of prior scaffold J. Med. Chem., Mar. 8, 2021 Genentech, South San Francisco, CA / Xenon

"compound 20"

Cryo-EM-characterized TRPA1 ion channel inh. Oral efficacy (10 mpk BID) in asthma model Rational design from literature starting point J. Med. Chem., Mar. 22, 2021 Genentech, South San Francisco, CA

GSK716 (13)

Mutant a1-antitrypsin folding corrector Sub-µM in cell, high predicted human %F From 2T component DEL + SBDD Bioorg. Med. Chem. Lett., Mar. 19, 2021 GlaxoSmithKline, Stevenage, UK / UCL

sisunatovir

Oral lung penetrant RSV fusion inhibitor Ph. II candidate (50 mg BID) for RSV infect. Opt. from literature starting point J. Med. Chem., Mar. 17, 2021 Reviral Ltd, Hertfordshire, UK



X-ray, PDB 7AEL

X-ray, PDB: 7KQD

discover together

drughunter.com info@drughunter.com